Variant Pharmaceuticals is a clinical-stage orphan drug company advancing 2-hydroxypropyl-β-cyclodextrin (2HPβCD) programs for two rare, progressive kidney diseases: Focal Segmental Glomerulosclerosis (FSGS) and Alport Syndrome (AS). Its lead program is VAR 200 (2HPβCD), and the company is pursuing both clinical and non-clinical development activities. Variant intends to use new financing to produce clinical supplies, execute a Phase 2a trial in patients with FSGS, support expanded access and subcutaneous delivery initiatives, and hire select personnel. The company secured financing to support these near-term development milestones. Variant was established in 2014 and is based in Weston, Florida.

Total raised

$10M

Funding rounds

1

Latest round

Equity

Latest activity

Dec 2018